Loading...

GNI Group

DB:3G6
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3G6
DB
¥42B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

GNI Group Ltd. researches, develops, manufactures, and sells pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • GNI Group has significant price volatility in the past 3 months.
3G6 Share Price and Events
7 Day Returns
-4.7%
DB:3G6
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-40.3%
DB:3G6
-10.2%
DE Biotechs
-6%
DE Market
3G6 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
GNI Group (3G6) -4.7% -11.2% -20.5% -40.3% -13.5% 12.8%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 3G6 underperformed the Biotechs industry which returned -10.2% over the past year.
  • 3G6 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
3G6
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for GNI Group's competitors could be found in our database.

Value

 Is GNI Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for GNI Group. This is due to cash flow or dividend data being unavailable. The share price is €21.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for GNI Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are GNI Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3G6 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥-14.81
TSE:2160 Share Price ** TSE (2019-04-18) in JPY ¥3010
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of GNI Group.

DB:3G6 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:2160 Share Price ÷ EPS (both in JPY)

= 3010 ÷ -14.81

-203.24x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GNI Group is loss making, we can't compare its value to the Europe Biotechs industry average.
  • GNI Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does GNI Group's expected growth come at a high price?
Raw Data
DB:3G6 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -203.24x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for GNI Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on GNI Group's assets?
Raw Data
DB:3G6 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥866.97
TSE:2160 Share Price * TSE (2019-04-18) in JPY ¥3010
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:3G6 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:2160 Share Price ÷ Book Value per Share (both in JPY)

= 3010 ÷ 866.97

3.47x

* Primary Listing of GNI Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GNI Group is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess GNI Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. GNI Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is GNI Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GNI Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is GNI Group expected to grow at an attractive rate?
  • Unable to compare GNI Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare GNI Group's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare GNI Group's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:3G6 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3G6 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3G6 Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
DB:3G6 Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 5,018 610 -200
2018-09-30 4,802 341 47
2018-06-30 4,095 45 -130
2018-03-31 3,310 17 -337
2017-12-31 2,648 -315 -175
2017-09-30 1,939 -470 -97
2017-06-30 1,473 -284 -111
2017-03-31 1,347 -327 -406
2016-12-31 1,306 -518 -513
2016-09-30 1,117 -858
2016-06-30 1,073 -514 -956
2016-03-31 1,093 -752

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if GNI Group is high growth as no earnings estimate data is available.
  • Unable to determine if GNI Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3G6 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from GNI Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3G6 Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
DB:3G6 Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 -14.81
2018-09-30 3.48
2018-06-30 -9.65
2018-03-31 -25.81
2017-12-31 -13.95
2017-09-30 -8.07
2017-06-30 -9.64
2017-03-31 -35.65
2016-12-31 -45.09
2016-09-30 -75.47
2016-06-30 -84.10
2016-03-31 -66.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if GNI Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine GNI Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. GNI Group's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. GNI Group's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess GNI Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
GNI Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has GNI Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare GNI Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • GNI Group does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare GNI Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare GNI Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
GNI Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from GNI Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3G6 Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 5,018.00 -200.00 2,998.00 530.00
2018-09-30 4,802.00 47.00 2,730.00 527.00
2018-06-30 4,095.00 -130.00 2,401.00 413.00
2018-03-31 3,310.00 -337.00 2,103.00 302.00
2017-12-31 2,648.00 -175.00 1,740.00 268.00
2017-09-30 1,939.00 -97.00 1,521.00 243.00
2017-06-30 1,473.00 -111.00 1,261.00 238.00
2017-03-31 1,347.00 -406.00 1,139.00 257.00
2016-12-31 1,306.00 -513.00 1,118.00 274.00
2016-09-30 1,117.00 -858.00 878.00 580.00
2016-06-30 1,073.00 -956.00 979.00 519.00
2016-03-31 1,093.00 -752.00 1,048.00 452.00
2015-12-31 1,016.00 -623.00 1,049.00 379.00
2015-09-30 928.00 -440.00 1,071.00 139.00
2015-06-30 814.00 -360.00 963.00 139.00
2015-03-31 651.00 -345.00 823.00 139.00
2014-12-31 474.00 -327.00 715.00 139.00
2014-09-30 334.00 -527.00 364.00 427.00
2014-06-30 254.00 -787.00 511.00 427.00
2014-03-31 202.00 -769.00 438.00 427.00
2013-12-31 183.00 -730.00 367.00 427.00
2013-09-30 165.00 -708.00 554.00 101.00
2013-06-30 147.00 -462.00 285.00 101.00
2013-03-31 156.00 -456.00 301.00 101.00
2012-12-31 161.00 -482.00 331.00 101.00
2012-09-30 157.00 -463.00 314.00 103.00
2012-06-30 140.00 -436.00 295.00 103.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • GNI Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • It is difficult to establish if GNI Group has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if GNI Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess GNI Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
GNI Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is GNI Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up GNI Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • GNI Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • GNI Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of GNI Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from GNI Group Company Filings, last reported 3 months ago.

DB:3G6 Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 13,718.00 2,332.00 4,869.00
2018-09-30 13,676.00 1,256.00 3,768.00
2018-06-30 13,430.00 1,270.00 3,917.00
2018-03-31 13,122.00 1,206.00 4,217.00
2017-12-31 13,481.00 1,321.00 4,192.00
2017-09-30 12,812.00 1,168.00 4,160.00
2017-06-30 10,113.00 1,012.00 8,621.00
2017-03-31 4,206.00 936.00 2,445.00
2016-12-31 4,533.00 678.00 2,599.00
2016-09-30 4,286.00 550.00 2,506.00
2016-06-30 4,357.00 563.00 2,633.00
2016-03-31 4,836.00 707.00 2,753.00
2015-12-31 5,127.00 678.00 3,022.00
2015-09-30 5,314.00 700.00 3,727.00
2015-06-30 5,541.00 730.00 3,902.00
2015-03-31 5,644.00 738.00 4,078.00
2014-12-31 5,784.00 509.00 4,950.00
2014-09-30 5,516.00 618.00 4,978.00
2014-06-30 5,516.00 295.00 5,012.00
2014-03-31 5,654.00 383.00 5,252.00
2013-12-31 3,972.00 402.00 3,550.00
2013-09-30 815.00 392.00 775.00
2013-06-30 1,176.00 395.00 1,167.00
2013-03-31 944.00 316.00 694.00
2012-12-31 1,030.00 365.00 827.00
2012-09-30 1,168.00 318.00 892.00
2012-06-30 1,303.00 325.00 1,000.00
  • GNI Group's level of debt (17%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (10.1% vs 17% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • GNI Group has sufficient cash runway for more than 3 years based on current free cash flow.
  • GNI Group has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -17% each year.
X
Financial health checks
We assess GNI Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. GNI Group has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is GNI Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from GNI Group dividends.
If you bought €2,000 of GNI Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate GNI Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate GNI Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3G6 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:3G6 Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as GNI Group has not reported any payouts.
  • Unable to verify if GNI Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of GNI Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as GNI Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess GNI Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can GNI Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. GNI Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of GNI Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ying Luo
AGE 53
TENURE AS CEO 9.8 years
CEO Bio

Dr. Ying Luo, Ph.D. is Chairman, Chief Executive Officer and President of Cullgen Inc. Dr. Luo has been the Chief Executive Officer, President and Representative Executive Officer of GNI Group Ltd. since June, 2009. The pre-clinical, clinical and regulatory teams recruited and supervised by him has successfully gained 6 IND approvals and conduct Phase I/II trials in China or US. Under his leadership, GNI Group had its first Class 1 drug Etuary® approved by China FDA in treating IPF in 2011 through expedited review process. Dr. Luo serves as President and Chief Executive Officer of Gene Networks Inc. He serves as the President at GNI USA, Inc. He co-founded Shanghai Genomics, Inc. in 2001 and serves as its General Manager. He served as Chief Operating Officer of GNI Ltd. He served as Chief Executive Officer and President of Shanghai Genomics, Inc. He joined Aviron Company and Clontech Laboratory. He served as Senior Director of Genomics in Rigel Pharmaceuticals before returning to China to found Shanghai Genomics, Inc. Dr. Luo held various positions at Clonetech. He serves as the Chairman of the Board at Shanghai Genomics, Inc. He has been working on protein-protein interaction related functional genomics technologies since 1992 and had many publications. He also holds the titles of Director of Functional Genomics at Chinese National Genome Centers at both Shanghai and Beijing. He is a faculty member of China Genome Center at Shanghai. Dr. Luo serves as an Adjunct Professor at Shanghai Jiaotong University. Dr. Luo is a frequently invited speaker at international biotech conferences and his story was covered on the front page of the Wall Street Journal in 2003. He has been a Director of GNI Group Ltd. since June 2005. and Gene Networks Inc. Later he built a nationwide orphan drug sales network in China. He also engineered several acquisitions for GNI, including Beijing Continent and Berkeley Advanced Biomaterials and investments into other joint ventures. In his career of 30 years, Dr. Luo has co-authored more than 35 research publications and been inventors of more than 16 patents. Dr. Luo completed his undergraduate education at Peking Union Medical College (Peking University) in 1982 and received his Ph.D. in Biomedical Sciences and Molecular Biology from the University of Connecticut Health Center in the U.S. in 1991 and postdoctoral research on HIV at UCSF in 1993.

CEO Compensation
  • Insufficient data for Ying to compare compensation growth.
  • Insufficient data for Ying to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the GNI Group management team in years:

18.3
Average Tenure
59
Average Age
  • The average tenure for the GNI Group management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Ying Luo

TITLE
CEO, President
AGE
53
TENURE
9.8 yrs

Kosuke Tashiro

TITLE
Co-Founder
TENURE
18.3 yrs

Cristin Print

TITLE
Co-Founder
TENURE
18.3 yrs

Stephen Charnock-Jones

TITLE
Co-Founder
TENURE
18.3 yrs

Thomas Eastling

TITLE
CFO, Representative Executive Officer & Director
AGE
59

Hiroyuki Sato

TITLE
Executive Officer & Director
AGE
64
Board of Directors

Ying Luo

TITLE
CEO, President
AGE
53
TENURE
13.8 yrs

Thomas Eastling

TITLE
CFO, Representative Executive Officer & Director
AGE
59
TENURE
6.1 yrs

Hiroyuki Sato

TITLE
Executive Officer & Director
AGE
64
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess GNI Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. GNI Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

GNI Group Ltd. researches, develops, manufactures, and sells pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. The company provides Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary for the treatment of radiation pneumonitis, which is in pilot study for Phase III clinical trials; Tamibarotene, a product for treating acute promyelocytic leukemia; and F351 that is in Phase II clinical trial for the treatment of liver fibrosis. In addition, the company is developing Etuary for the treatment of diabetic nephropathy and connective tissue disease associated interstitial lung disease; and F573 for acute liver failure and acute-on-chronic liver failure. Further, it is developing diabetic nephropathy; and connective tissue disease associated interstitial lung disease, which are in investigational new drug application stage. GNI Group Ltd. was founded in 2001 and is headquartered in Tokyo, Japan.

Details
Name: GNI Group Ltd.
3G6
Exchange: DB
Founded: 2001
¥331,099,669
13,862,686
Website: http://www.gnipharma.com
Address: GNI Group Ltd.
Nihonbashi-Honcho YS Building,
3rd Floor,
Tokyo,
103-0023,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 2160 Common Stock The Tokyo Stock Exchange JP JPY 31. Aug 2007
OTCPK GNII.F Common Stock Pink Sheets LLC US USD 31. Aug 2007
DB 3G6 Common Stock Deutsche Boerse AG DE EUR 31. Aug 2007
Number of employees
Current staff
Staff numbers
350
GNI Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 21:16
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/14
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.